Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series.

ABSTRACT:

Introduction

Long-acting injectable buprenorphine (LAIB) products are being increasingly used to treat patients with opioid dependence. Limited data is available on the severity or timespan (time to onset, peak, duration) of withdrawal signs and symptoms following discontinuation of treatment.

Methods

Participants aiming to discontinue long-term LAIB treatment commenced the study on the day of their final dose of Buvidal® 64 mg Monthly. Participants were monitored with weekly assessments of withdrawal severity, cravings, general health, and patient experience measures for up to 16 weeks after last dose.

Results

Fifteen participants - those who remained for at least four weeks after the last LAIB dose - were included in the study. There was minimal increase in withdraw

SUBMITTER: Hayes V 

PROVIDER: S-EPMC12018199 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature